Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Autor: Jane Perlmutter, Victoria S. Blinder, Laleh Amiri-Kordestani, Jared C. Foster, Eileen Rakovitch, Eric P. Winer, Angelo DiLeo, Julia White, Anthony D. Elias, Ana F. Best, Lynn Pearson Butler, Sara M. Tolaney, Lawrence Baizer, Patricia A. Spears, Elena Schwartz, David Cameron, Elizabeth Garrett-Mayer, Neelima Denduluri, Elizabeth S. Frank, Larissa A. Korde, E. Shelley Hwang, Nadine Tung, Judith M Bliss

Publikováno v: M Tolaney, S, Garrett-Mayer, E, White, J, S. Blinder, V, C. Foster, J, Amiri Kordestani, L, Hwang, S, M. Bliss, J, Rakovitch, E, Perlmutter, J, A. Spears, P, Frank, E, M. Tung, N, D. Elias, A, Cameron, D A, Denduluri, N, F. Best, A, Di Leo, A, Baizer, L, Pearson Butler, L, Schwartz, E, P Winer, E & A. Korde, L 2021, ' Updated standardized definitions for efficacy endpoints in adjuvant breast cancer clinical trials: STEEP Version 2.0 ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.20.03613
J Clin Oncol

PURPOSEThe Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer clinical trials and improvem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::462fd891363195e2418ad331df8718fa
https://doi.org/10.1200/jco.20.03613